![Chapter 6 Final Perspectives and Future Research Opportunities | Using Disaggregated Socioeconomic Data in Air Passenger Demand Studies |The National Academies Press Chapter 6 Final Perspectives and Future Research Opportunities | Using Disaggregated Socioeconomic Data in Air Passenger Demand Studies |The National Academies Press](https://nap.nationalacademies.org/books/25411/gif/111.gif)
Chapter 6 Final Perspectives and Future Research Opportunities | Using Disaggregated Socioeconomic Data in Air Passenger Demand Studies |The National Academies Press
![BA.4 and BA.5 subvariants of COVID show higher pathogenicity and higher resistance to natural and vaccine-induced immunity – ICReDD: Institute for Chemical Reaction Design and Discovery, Hokkaido University (WPI-ICReDD) BA.4 and BA.5 subvariants of COVID show higher pathogenicity and higher resistance to natural and vaccine-induced immunity – ICReDD: Institute for Chemical Reaction Design and Discovery, Hokkaido University (WPI-ICReDD)](https://www.icredd.hokudai.ac.jp/wp/wp-content/uploads/2022/10/Picture1-1-1280x1277.jpg)
BA.4 and BA.5 subvariants of COVID show higher pathogenicity and higher resistance to natural and vaccine-induced immunity – ICReDD: Institute for Chemical Reaction Design and Discovery, Hokkaido University (WPI-ICReDD)
![Energies | Free Full-Text | Energy–Water–Carbon Nexus Study for the Optimal Design of Integrated Energy–Water Systems Considering Process Losses Energies | Free Full-Text | Energy–Water–Carbon Nexus Study for the Optimal Design of Integrated Energy–Water Systems Considering Process Losses](https://pub.mdpi-res.com/energies/energies-15-08605/article_deploy/html/images/energies-15-08605-g004.png?1668744032)
Energies | Free Full-Text | Energy–Water–Carbon Nexus Study for the Optimal Design of Integrated Energy–Water Systems Considering Process Losses
![CUSTOMIZE: OVERALL RESULTS FROM A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY EXAMINING IMPLEMENTATION OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING INJECTABLE FOR HIV TREATMENT IN US HEALTHCARE SETTINGS; FINAL PATIENT AND PROVIDER DATA CUSTOMIZE: OVERALL RESULTS FROM A HYBRID III IMPLEMENTATION-EFFECTIVENESS STUDY EXAMINING IMPLEMENTATION OF CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING INJECTABLE FOR HIV TREATMENT IN US HEALTHCARE SETTINGS; FINAL PATIENT AND PROVIDER DATA](https://www.natap.org/2021/images/012922/0129221.gif)